The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
Here's a roundup of top developments in the biotech space over the last 24 hours.
Alnylam Pharma Reports Comments On FDA Approval Of Leqvio Approved To Reduce Low-Density Lipoprotein Cholesterol
– Leqvio® Becomes Fourth RNAi Therapeutic Approved by U.S. FDA and First and Only for Lowering LDL-C in Atherosclerotic Cardiovascular Disease (ASCVD) Which Can Affect Up to 30 Million Americans
Alnylam Pharma Highlights Publication Of Third Annual Patient Access Philosophy Report Showing Access To Approved Therapies As Co. Enters New Geographies
– Annual progress report highlights the breadth of innovative and collaborative initiatives that support accessibility of RNAi therapeutics for people who can benefit worldwide –
CAMBRIDGE, Mass.--(BUSINESS
The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail
Here's a roundup of top developments in the biotech space over the last 24 hours:
2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022
Biotech stocks are risky investments and to make a profit informed decision-making is needed.
BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.
Read Why Analysts Are Going Bullish On This Large-Cap Pharma Stock
RBC Capital has upgraded Alnylam Pharmaceuticals Inc (NASDAQ:
Expert Ratings For Alnylam Pharmaceuticals
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Needham Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $205
Needham analyst Joseph Stringer maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $180 to $205.
Alnylam Pharmaceuticals Initiates KARDIA-2 Phase 2 Study Of Investigational Zilebesiran (ALN-AGT) In Patients With Inadequately Controlled Hypertension
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-2, a global Phase 2 study to evaluate the efficacy and safety of zilebesiran (formerly known
